IMNNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Imunon, Inc.

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026

$0.98−0.04 (-3.43%)

Close on Oct 19, 2026

Market cap: $4.95M
P/E (TTM): –
Dividend yield: –

Imunon, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM FY 2023 2023-12-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30	TTM Q2 2016 2016-06-30	TTM Q1 2016 2016-03-31	TTM FY 2015 2015-12-31	TTM Q3 2015 2015-09-30	TTM Q2 2015 2015-06-30
Revenue	–	–	–	–	–	–	–	–	–	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	–	–	–	–	–	–	–	–	–	–
Research & Development	7.95	7.78	7.52	8.92	11	12	13	12	11	12	12	12	11	11	10	10	11	11	12	13	13	13	12	11	12	12	13	14	13	13	14	15	15	15	15	13	14	15	15	17
General & Administrative	6.86	6.87	7.01	7.10	7.76	7.49	7.99	8.25	9.74	14	12	11	11	11	10	9.44	8.74	7.64	7.34	7.39	7.62	8.00	8.72	8.85	10	9.70	8.77	7.98	5.61	5.89	5.46	5.78	6.13	6.53	6.26	6.24	6.52	6.69	7.39	7.96
Operating Expenses	15	15	15	16	18	19	21	20	21	25	24	23	22	22	21	20	20	19	19	20	21	21	21	20	22	22	21	22	18	19	19	20	21	21	21	20	20	21	23	25
Operating Income	-15	-15	-15	-16	-18	-19	-21	-20	-21	-25	-23	-22	-21	-21	-20	-19	-19	-18	-18	-20	-20	-21	-21	-19	-22	-21	-21	-21	-18	-18	-19	-20	-20	-21	-20	-19	-20	-21	-22	-25
Interest Expense	–	–	–	–	–	–	–	–	0.20	5.03	–	–	–	0.57	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	0.45	0.15	0.30	0.73	0.50	0.25	0.09	0.03	0.02	0.01	0.01	0.02	0.07	0.14	0.26	0.38	0.44	0.49	0.47	0.40	0.36	0.26	0.16	0.09	0.03	0.00	0.01	0.01	0.03	0.06	0.08	0.11	0.19	0.34	0.57
Other Non-Operating Income	–	0.16	–	–	–	0.51	0.22	0.53	0.24	-13	-4.78	-5.16	-5.47	-1.15	-1.10	-4.66	-4.86	-4.84	-4.95	-1.13	-0.89	1.90	1.88	1.34	1.45	-1.24	-1.05	-1.69	-2.74	-1.93	-3.15	-2.69	-1.21	-1.40	-1.71	-0.92	-1.56	-1.61	-1.07	-1.32
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.40	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	0.06	0.02	0.16	-0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-15	-14	-14	-16	-18	-19	-19	-18	-20	-36	-27	-26	-26	-21	-20	-22	-22	-21	-22	-19	-20	-17	-8.27	-7.45	-9.77	-12	-22	-23	-21	-20	-22	-23	-21	-22	-22	-20	-21	-22	-23	-26
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-12	–	–	–	-21	-22	-23	-21	-22	-22	-20	-21	-22	-23	-26
EPS (Basic)(per share)	-5.59	-6.83	-9.57	-12.17	-17.66	-16.94	-12.44	-9.05	-2.16	-5.03	–	–	–	–	-6.39	-9.05	-10.80	-10.08	-11.11	-11.26	-12.91	-11.55	-5.33	-5.48	-8.03	-10.20	–	–	–	–	–	–	–	–	-270.27	-294.65	-358.47	-393.98	-416.75	-497.07
EPS (Diluted)(per share)	-5.59	-6.83	-9.57	-12.17	-17.66	-16.94	-12.44	-9.05	-2.16	-5.03	-4.29	-4.32	-4.35	-3.83	-4.34	-7.04	-8.84	-10.08	-11.11	-11.26	-12.91	-11.55	-5.33	-5.48	-8.03	-10.20	–	–	–	–	–	–	–	–	-270.27	-294.65	-358.47	-393.98	-416.75	-497.07
Shares Outstanding (Basic, Weighted)(shares)	3.04	2.12	1.71	1.29	1.13	1.10	5.18	7.20	9.05	7.14	6.41	6.07	5.76	5.43	3.94	3.06	2.13	2.13	1.93	1.72	1.56	1.46	1.32	1.26	1.21	1.17	1.14	0.97	0.81	0.51	0.33	0.23	0.12	0.12	0.09	0.07	0.06	0.06	0.06	0.05
Shares Outstanding (Diluted, Weighted)(shares)	3.04	2.12	1.71	1.29	1.13	1.10	5.18	7.20	9.05	7.14	6.41	6.07	5.76	5.43	4.61	3.74	2.81	2.13	1.93	1.72	1.56	1.46	1.32	1.26	1.21	1.17	1.14	0.97	0.81	0.51	0.33	0.23	0.12	0.12	0.09	0.07	0.06	0.06	0.06	0.05
EBITDA	–	–	–	–	–	–	–	–	–	-25	-23	-22	-21	-20	-20	-19	-18	-18	-18	-19	-20	-20	-20	-19	-21	-21	-21	-21	-17	-18	-18	-19	-19	-20	-20	-19	-19	-20	-22	-24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -256.4%

Financial strength

Current ratio: 1.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 115.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.47
Dividend yield: –